All In Biotech

Drug Trial Radar · NCT06549114

Leniolisib for Immune Dysregulation in PIDs

A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Oct 21, 2024

Primary completion

Jun 23, 2026

Study completion Jun 23, 2026

Sponsor

Lead sponsor
Pharming Technologies B.V.Industry
Sponsor type
Industry
First posted
Aug 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an exploratory, non-randomized, open-label, within-patient dose escalation study. The primary objective is to assess safety and tolerability of leniolisib. Secondary objectives include assessments of PK/PD, and to explore clinical efficacy measures with administration of three different dose levels of leniolisib.

Conditions

  • Primary Immunodeficiency Disorders (PIDs)

Interventions

  • LeniolisibDrug

    The doses selected will range from 10 to 70 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 140 mg per day).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs) , and Adverse Events (AEs)Time frame: From Baseline to the end of 20 weeks of Treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institute of Health

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.